JP2008531746A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531746A5
JP2008531746A5 JP2008500768A JP2008500768A JP2008531746A5 JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5 JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5
Authority
JP
Japan
Prior art keywords
tweak
antibody
receptor
tweak receptor
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008500768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007547 external-priority patent/WO2006096487A2/en
Publication of JP2008531746A publication Critical patent/JP2008531746A/ja
Publication of JP2008531746A5 publication Critical patent/JP2008531746A5/ja
Withdrawn legal-status Critical Current

Links

JP2008500768A 2005-03-07 2006-03-02 Tweak及びfn14活性を調節するための方法及び組成物 Withdrawn JP2008531746A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013271694A Division JP2014111605A (ja) 2005-03-07 2013-12-27 Tweak及びfn14活性を調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2008531746A JP2008531746A (ja) 2008-08-14
JP2008531746A5 true JP2008531746A5 (https=) 2009-04-16

Family

ID=36953868

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500768A Withdrawn JP2008531746A (ja) 2005-03-07 2006-03-02 Tweak及びfn14活性を調節するための方法及び組成物
JP2013271694A Pending JP2014111605A (ja) 2005-03-07 2013-12-27 Tweak及びfn14活性を調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013271694A Pending JP2014111605A (ja) 2005-03-07 2013-12-27 Tweak及びfn14活性を調節するための方法及び組成物

Country Status (12)

Country Link
US (2) US20080286271A1 (https=)
EP (1) EP1853312B1 (https=)
JP (2) JP2008531746A (https=)
KR (3) KR20150031459A (https=)
CN (2) CN102225200A (https=)
AU (1) AU2006220825A1 (https=)
BR (1) BRPI0608012A2 (https=)
CA (1) CA2597485A1 (https=)
IL (1) IL185180A0 (https=)
RU (1) RU2007137060A (https=)
WO (1) WO2006096487A2 (https=)
ZA (1) ZA200707489B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
EP1853312B1 (en) * 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20100284933A1 (en) * 2006-10-16 2010-11-11 Biogen Idec Ma Inc. Biomarkers of Multiple Sclerosis
EP2545938A1 (en) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトtweak抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
MY204672A (en) * 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280231A1 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
PT1626058E (pt) * 1999-03-08 2008-02-15 Genentech Inc Composições e métodos para o diagnóstico de tumores
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1811838A4 (en) * 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
EP1853312B1 (en) * 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity

Similar Documents

Publication Publication Date Title
JP2008531746A5 (https=)
Steeland et al. A new venue of TNF targeting
US10925969B2 (en) Anti-BCMA polypeptides and proteins
CA2386463C (en) April receptor (bcma) and uses thereof
JP5837730B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
CA3108915A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CN105622754B (zh) Fc受体结合蛋白
CA2558371C (en) Methods of modulating immune responses by modulating tim-1 and tim-4 function
PL207501B1 (pl) Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
Benucci et al. Tumor necrosis factors blocking agents: analogies and differences
KR20190115042A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US11773177B2 (en) Variant antibodies that bind OX40
US20220288226A1 (en) Methods and compositions to treat autoimmune diseases and cancer
CN116847887A (zh) 治疗自身免疫性疾病和癌症的方法和组合物
RU2007137060A (ru) Способы и композиции для модуляции активности tweak и fn14
TW200948377A (en) Affinity matured CRIg variants
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
Scheinberg et al. The potential role of blisibimod for the treatment of systemic lupus erythematosus
CN101371923B (zh) Baff受体(bcma),一种免疫调节剂
HK40000997B (en) Pan-elr+ cxc chemokine antibodies
HK40000997A (en) Pan-elr+ cxc chemokine antibodies
Das Characterisation of heteromers and oligomers in the TNF family of ligands and receptors